Cargando…

Exposure–Response Analysis of Necitumumab Efficacy in Squamous Non‐Small Cell Lung Cancer Patients

We sought to describe the exposure–response relationship of necitumumab efficacy in squamous non‐small cell lung cancer patients and evaluate intrinsic and extrinsic patient descriptors that may guide dosing. SQUIRE was a phase III study comparing necitumumab in combination with gemcitabine and cisp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chigutsa, E, Long, AJ, Wallin, JE
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572351/ https://www.ncbi.nlm.nih.gov/pubmed/28569042 http://dx.doi.org/10.1002/psp4.12209

Ejemplares similares

Population Pharmacokinetics of Necitumumab in Cancer Patients
por: Long, Amanda, et al.
Publicado: (2016)

Clinical potential of necitumumab in non-small cell lung carcinoma
por: Genova, Carlo, et al.
Publicado: (2016)

Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
por: Thakur, Manish K, et al.
Publicado: (2017)

The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives
por: Bly, Christopher A., et al.
Publicado: (2018)

Lung squamous cell carcinoma with severe hypomagnesemia due to cisplatin plus gemcitabine in combination with necitumumab therapy: A case report
por: Nakao, Akira, et al.
Publicado: (2021)

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
por: Elez, E, et al.
Publicado: (2016)

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
por: Murata, Yasunori, et al.
Publicado: (2023)

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
por: Park, Keunchil, et al.
Publicado: (2017)

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer
por: Paz-Ares, L., et al.
Publicado: (2016)

Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer
por: Rodier, Thomas, et al.
Publicado: (2022)

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer
por: Hida, Toyoaki, et al.
Publicado: (2017)

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer
por: Huemer, Florian, et al.
Publicado: (2018)

Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer
por: Fernández-Teruel, Carlos, et al.
Publicado: (2021)

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
por: Morcos, Peter N., et al.
Publicado: (2018)

Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis
por: Ljubicic, Lidija, et al.
Publicado: (2023)

Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis
por: Xiao, Xian, et al.
Publicado: (2022)

Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers
por: Tian, Yijun, et al.
Publicado: (2017)

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease
por: Gueorguieva, Ivelina, et al.
Publicado: (2023)

Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer
por: Yagishita, Shigehiro, et al.
Publicado: (2015)

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
por: Ricciardi, Serena, et al.
Publicado: (2009)

Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
por: Melosky, Barbara
Publicado: (2014)

Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2015)

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
por: Gao, Guanghui, et al.
Publicado: (2022)

Efficacy of Surgical Treatment for Brain Metastasis in Patients with Non-Small Cell Lung Cancer
por: Kim, Sang Young, et al.
Publicado: (2015)

Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
por: Ang, Yvonne LE, et al.
Publicado: (2016)

Anti-PDL1 effect in squamous non-small cell lung cancer
por: Rahouma, Mohamed, et al.
Publicado: (2020)

Efficacy analysis of targeted nanodrug for non-small cell lung cancer therapy
por: Li, Tongtong, et al.
Publicado: (2022)

Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
por: Melosky, Barbara
Publicado: (2017)

Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
por: Fujimoto, Daichi, et al.
Publicado: (2023)

Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer
por: Ivanina Foureau, Anna V., et al.
Publicado: (2022)

Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
por: Rothwell, Ben, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China
por: Zhang, Xin, et al.
Publicado: (2023)

Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis
por: Kim, Jung Han, et al.
Publicado: (2018)

Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China
por: Xie, Qian, et al.
Publicado: (2022)

Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Maarof, Nian N. N., et al.
Publicado: (2021)

Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer
por: Shi, Liang, et al.
Publicado: (2022)

Correlation Between Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphisms and Pemetrexed Chemotherapy Efficacy/Toxicity in Non-Squamous Non-Small Cell Lung Cancer
por: Lan, Gaochen, et al.
Publicado: (2017)

Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study
por: Gu, Xiaodong, et al.
Publicado: (2022)

Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
por: Stathopoulos, G. P., et al.
Publicado: (2011)

Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer
por: Russo, Alessandro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lbd3vfbvgo9g6oii24oju73607